Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KURA Kura Oncology

Market Closed 10-23 16:00:00 EDT

9.61

-0.25

-2.54%

盘后9.61

+0.000.00%

19:30 EDT

High9.84	Low9.28	Vol1.56M
Open9.80	D1 Closing9.86	Amplitude5.65%
Mkt Cap853.12M	Tradable Cap678.49M	Total Shares88.77M
T/O14.91M	T/O Rate2.22%	Tradable Shares70.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology","latestPrice":9.61,"timestamp":1792785600000,"preClose":9.86,"halted":0,"volume":1564980,"hourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.61,"latestTime":"19:30 EDT","volume":20330,"amount":195371.1262,"timestamp":1792798203866,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025354969574036514,"floatShares":70602200,"shares":88774365,"eps":-3.36681,"marketStatus":"Market Closed","change":-0.25,"latestTime":"10-23 16:00:00 EDT","open":9.8,"high":9.84,"low":9.2831,"amount":14914783.6683,"amplitude":0.056481,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.36681,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":9.86,"preHourTrading":{"tag":"盘前","latestPrice":9.8503,"preClose":9.86,"latestTime":"08:57 EDT","volume":1211,"amount":11728.7772,"timestamp":1792760271805,"change":-0.0097,"changeRate":-0.000984,"amplitude":0.140974},"postHourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.61,"latestTime":"19:30 EDT","volume":20330,"amount":195371.1262,"timestamp":1792798203866,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0157755529100454,"impliedVol":1.0203,"impliedVolPercentile":0.7251},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"2677676815","title":"3 Undervalued Small Caps With Insider Activity To Watch Closely","url":"https://stock-news.laohu8.com/highlight/detail?id=2677676815","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677676815?lang=en_us&edition=fundamental","pubTime":"2026-10-21 19:09","pubTimestamp":1792580972,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet it has shown a 12% rise over the past year, with earnings projected to grow by 17% annually in the coming years. In this context of steady growth and positive outlooks, identifying small-cap stocks that are undervalued and exhibit insider activity can offer intriguing opportunities for investors seeking potential value plays.","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kura/kura-oncology/news/3-undervalued-small-caps-with-insider-activity-to-watch-clos","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kura/kura-oncology/news/3-undervalued-small-caps-with-insider-activity-to-watch-clos","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KURA","PMTS","BK4505","BK4139","BK4170","BK4184","ALRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675359588","title":"Kura Oncology-Backed Caspian Advances KO-7246 Toward Phase 1 Diabetes Proof-of-Concept Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2675359588","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675359588?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:33","pubTimestamp":1791891230,"startTime":"0","endTime":"0","summary":"Kura Oncology-backed Caspian advances KO-7246 toward Phase 1 diabetes proof-of-concept studyKura Oncology outlined a development plan for KO-7246, an oral menin inhibitor for diabetes, with an investo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL6nvvTd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","SG9999014021.USD","BK4505","BK4112","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BCDF","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356090","title":"Kura Oncology - Ind-Enabling Development Underway for Phase 1 Proof-of-Concept Study of Ko-7246","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675356090?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891013,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Z13X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675094356","title":"Caspian Therapeutics and Kura Oncology Outline Ko-7246 Development Strategy in Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2675094356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675094356?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891013,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nFWN45Z13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675351620","title":"Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2675351620","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675351620?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891000,"startTime":"0","endTime":"0","summary":"– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/13/3379572/35186/en/caspian-therapeutics-and-kura-oncology-outline-ko-7246-development-strategy-in-diabetes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673097606","title":"Kura Oncology-Backed Caspian Plans Phase 1 Study of Diabetes Drug Candidate KO-7246","url":"https://stock-news.laohu8.com/highlight/detail?id=2673097606","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673097606?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:15","pubTimestamp":1791371725,"startTime":"0","endTime":"0","summary":"Kura Oncology-backed Caspian plans Phase 1 study of diabetes drug candidate KO-7246Kura Oncology announced an Oct. 13, 2026 investor webcast with Caspian Therapeutics to outline Caspian’s launch.Manag","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL3GhQPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","BK4139","IE00BKPKM429.USD","BK4505","IE00BN0W2W23.USD","BCDF","BK4585","LU2095319765.USD","BK4112","NDAQ","KURA","LU0314104364.USD","IE00BQXX3F31.USD","SG9999014013.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672192077","title":"Kura Oncology Grants Inducement Stock Options for 128,250 Shares to Nine New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2672192077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672192077?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:30","pubTimestamp":1790940614,"startTime":"0","endTime":"0","summary":"Kura Oncology grants inducement stock options for 128,250 shares to nine new hiresKura Oncology granted nonstatutory stock options covering 128,250 shares to nine new employees on Oct. 1, 2026.Options","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL59ylpK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","SG9999014005.SGD","SG9999014013.SGD","BCDF","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","BK4585","BK4505","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","KURA","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4139","IE00BQXX3D17.EUR","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719298","title":"Press Release: Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719298","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719298?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:30","pubTimestamp":1790940600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the \"Company\") (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEPQ","TQQQ","MNQmain","QQQY","QID","BK4505","NDX","BK4022","QQQJ","QYLG","QQQE","IYW","GPIQ","QQQA","SQQQ","FTEC","PSQ","NVIW.SI","BK4139","TECS","QQQM","ONEQ","QQQ","QDTE","BK4232","QLD","03086","NQmain","R","KURA",".IXIC","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672763558","title":"Kura Oncology Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672763558","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672763558?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:55","pubTimestamp":1790866500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KURA/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672775521","title":"JPMorgan Initiates Kura Oncology at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2672775521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672775521?lang=en_us&edition=fundamental","pubTime":"2026-10-01 17:45","pubTimestamp":1790847921,"startTime":"0","endTime":"0","summary":"Kura Oncology (KURA) has an average rating of buy and mean price target of $31.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KURA","JPM","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672275323","title":"Kura Oncology initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672275323","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672275323?lang=en_us&edition=fundamental","pubTime":"2026-10-01 16:45","pubTimestamp":1790844309,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of Kura Oncology (KURA) with an Overweight rating and $30 price target The firm believes Komzifti provides a “floor” fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-initiated-with-an-overweight-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297093","title":"Kura Oncology, - Caspian and Kura Announce Ko-7246 as Potential Best-in-Class Menin Inhibitor for Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671297093?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:16","pubTimestamp":1790673369,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45K156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297066","title":"Kura Oncology-Backed Caspian Advances KO-7246 Menin Inhibitor Toward First-in-Human Diabetes Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297066","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671297066?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:15","pubTimestamp":1790673318,"startTime":"0","endTime":"0","summary":"Kura Oncology-backed Caspian advances KO-7246 menin inhibitor toward first-in-human diabetes trialsKura Oncology highlighted new preclinical results for KO-7246, positioning it as a menin inhibitor ai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL7x71ts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","KURA","BK4505","IE00BQXX3F31.USD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","BK4588","SG9999014021.USD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","LU2095319765.USD","BK4139","NDAQ","LU2210150020.SGD","BK4585","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670243534","title":"Kura Oncology CSO Francis Burrows Disposes of Common Shares Worth $224,435.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2670243534","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670243534?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:05","pubTimestamp":1790366757,"startTime":"0","endTime":"0","summary":"Kura Oncology CSO Francis Burrows disposes of common shares worth $224,435.31Chief Scientific Officer Francis Burrows sold 20,726 Kura Oncology common shares on Sept. 24, 2026 at $10.8325.Burrows exer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL2MRGZr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kura Oncology CSO Francis Burrows Disposes of Common Shares Worth $224,435.31","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666151465","title":"Kura Oncology CFO Jennifer Fulk Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666151465","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666151465?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:25","pubTimestamp":1789071948,"startTime":"0","endTime":"0","summary":"Kura Oncology CFO Jennifer Fulk files initial beneficial ownership statementKura Oncology CFO Jennifer Fulk filed an initial Form 3 statement on Sept. 8, 2026.Disclaimer:This news brief was created by","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL79vWqc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666968015","title":"Kura Oncology (KURA) Receives a Buy from Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2666968015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666968015?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:55","pubTimestamp":1789044952,"startTime":"0","endTime":"0","summary":"In a report released today, from Leerink Partners maintained a Buy rating on Kura Oncology, with a price target of $12.15. Currently, the analyst c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kura-oncology-kura-receives-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kura-oncology-kura-receives-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587553","title":"Kura Oncology Launches Caspian Therapeutics, Targets Clinical Proof-of-Concept for Diabetes Drug KO-7246 After USD 50 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587553","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587553?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:04","pubTimestamp":1788951897,"startTime":"0","endTime":"0","summary":"Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financingKura Oncology launched Caspian Therapeutics with USD 50 million f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL29PYsK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","BCDF","IE00BN0W2W23.USD","BK4585","BK4505","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4112","KURA","BK4588","LU2095319765.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458207","title":"Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458207","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458207?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA54BNLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320934","title":"Kura Oncology Names Jennifer Fulk Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320934","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320934?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869102,"startTime":"0","endTime":"0","summary":"Kura Oncology (KURA) said Tuesday it has appointed Jennifer Fulk as finance chief, effective immediately.Fulk previously worked as CFO at Soleno Therapeutics (SLNO), among others, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","SLNO","CFO","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327431","title":"Kura Oncology Appoints Jennifer Fulk as New CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327431","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327431?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867030,"startTime":"0","endTime":"0","summary":"An announcement from Kura Oncology ( ($KURA) ) is now available. Effective September 8, 2026, Kura Oncology appointed industry veteran Jennifer Ful...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kura-oncology-appoints-jennifer-fulk-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kura-oncology-appoints-jennifer-fulk-as-new-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":-0.1295},{"period":"3month","weight":-0.0751},{"period":"6month","weight":0.0378},{"period":"1year","weight":0.056},{"period":"ytd","weight":-0.0751}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.002309},{"month":2,"riseRate":0.545455,"avgChangeRate":0.031825},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.033425},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.021049},{"month":5,"riseRate":0.545455,"avgChangeRate":0.027851},{"month":6,"riseRate":0.545455,"avgChangeRate":0.041051},{"month":7,"riseRate":0.454545,"avgChangeRate":0.017727},{"month":8,"riseRate":0.545455,"avgChangeRate":0.097344},{"month":9,"riseRate":0.454545,"avgChangeRate":0.096085},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.079457},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.00367}],"exchange":"NASDAQ","name":"Kura Oncology","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kura Oncology,KURA,Kura Oncology股票,Kura Oncology股票老虎,Kura Oncology股票老虎国际,Kura Oncology行情,Kura Oncology股票行情,Kura Oncology股价,Kura Oncology股市,Kura Oncology股票价格,Kura Oncology股票交易,Kura Oncology股票购买,Kura Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction